主要文件

查看所有文档

SML2104

Ambrisentan

Name: Ambrisentan
Brand: SIGMA

≥98% (HPLC), Endothelin ETA Receptor Antagonist, powder

别名:

(+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₂₂H₂₂N₂O₄

化学文摘社编号:

177036-94-1

分子量:

378.42

NACRES:

NA.77

UNSPSC Code:

41121706

MDL number:

MFCD08672619

Assay:

≥98% (HPLC)

Form:

powder

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

产品名称

Ambrisentan, ≥98% (HPLC)

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D +160 to +190°, c = 0.5 in methanol

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

CC1=CC(C)=NC(O[C@@H](C(C2=CC=CC=C2)(OC)C3=CC=CC=C3)C(O)=O)=N1

InChI

1S/C22H22N2O4/c1-15-14-16(2)24-21(23-15)28-19(20(25)26)22(27-3,17-10-6-4-7-11-17)18-12-8-5-9-13-18/h4-14,19H,1-3H3,(H,25,26)

InChI key

OUJTZYPIHDYQMC-UHFFFAOYSA-N

说明

Biochem/physiol Actions

Ambrisentan is an endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension (PAH). It is 200-fold selective for the the ETA receptor subtype with a Ki of 1 nM for ETA and a Ki of 195 nM for ETB.

Endothelin ETA Receptor Antagonist; Antihypertensive; Pulmonary Hypertension Treatment

Still not finding the right product?

Explore all of our products under

pictograms

GHS08

signalword

Danger

hcodes

H360FD

pcodes

P201 - P202 - P280 - P308 + P313 - P405 - P501

Hazard Classifications

Repr. 1A

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Differential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro.

Johanna Weiss et al.

European journal of pharmacology, 660(2-3), 298-304 (2011-04-20)

The safety and effectiveness of drugs used to treat chronic diseases critically depend on their propensity to interact with co-administered drugs. Induction of enzymes and drug transporters involved in the clearance and distribution of drugs may critically reduce exposure with

Functional estimation of endothelin-1 receptor antagonism by bosentan, macitentan and ambrisentan in human pulmonary and radial arteries in vitro.

James A Angus et al.

European journal of pharmacology, 804, 111-116 (2017-03-17)

Endothelin receptor antagonists are approved for pulmonary arterial hypertension. Development of selective ET Human isolated pulmonary (i.d. 5.5mm) and human radial (i.d. 3.23mm) artery ring segments were mounted in organ baths for isometric force measurement. Single concentration-contraction curves to endothelin-1

Ambrisentan: a review of its use in pulmonary arterial hypertension.

Belinda N Rivera-Lebron et al.

Therapeutic advances in respiratory disease, 11(6), 233-244 (2017-04-21)

Pulmonary arterial hypertension (PAH) is a progressive disease defined by an elevation in pulmonary arterial pressure that can lead to right heart failure and death. Ambrisentan is a selective endothelin receptor antagonist approved for the treatment of idiopathic, heritable PAH

查看所有相关文献

全球贸易项目编号

货号	GTIN
SML2104-10MG	04061835492817
SML2104-50MG	04061835492824